DISARM Therapeutics patent, SARM1 inhibitors, neuroprotection
USPTO Patent Grants - Biotech (C12N)
Summary
DISARM Therapeutics patent, SARM1 inhibitors, neuroprotection
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and compositions for neuroprotection
Grant US12595481B2 Kind: B2 Apr 07, 2026
Assignee
DISARM THERAPEUTICS, INC.
Inventors
Liza Leventhal, Thomas Engber, Raul Eduardo Krauss, Rajesh Devraj, Robert Owen Hughes, Todd Bosanac, Sudhir Agrawal, Marco A. Passini
Abstract
The present invention relates to compositions and methods for treating neurodegeneration and neurodegenerative diseases associated with axonal degeneration. Neurodegeneration and neurodegenerative diseases associated with axonal degeneration are treated with therapies comprising SARM1 inhibitors such as SARM1 antisense oligonucleotides.
CPC Classifications
C12N 15/113 C12N 2310/11 C12N 2310/3125 C12N 2310/314 C12N 2310/315 C12N 2310/316 C12N 2310/531 C12N 2310/322 C12N 2310/341 C12N 2310/345 C12N 2310/3525 A61K 31/7088
Filing Date
2020-11-25
Application No.
17778567
Claims
18
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.